NASDAQ:NYXH Nyxoah (NYXH) Stock Price, News & Analysis → Warning: this could blow your mind (From DTI) (Ad) Free NYXH Stock Alerts $13.49 +0.23 (+1.73%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$13.16▼$13.6750-Day Range$4.41▼$19.5052-Week Range$4.00▼$20.00Volume12,713 shsAverage Volume65,799 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice Target$20.60 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get Nyxoah alerts: Email Address Nyxoah MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.83 Rating ScoreUpside/Downside52.7% Upside$20.60 Price TargetShort InterestBearish3.14% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.42Based on 8 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.25 out of 5 stars 4.4 Analyst's Opinion Consensus RatingNyxoah has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $20.60, Nyxoah has a forecasted upside of 52.7% from its current price of $13.49.Amount of Analyst CoverageNyxoah has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.0 Short Interest Percentage of Shares Shorted3.14% of the float of Nyxoah has been sold short.Short Interest Ratio / Days to CoverNyxoah has a short interest ratio ("days to cover") of 4.9.Change versus previous monthShort interest in Nyxoah has recently increased by 65.57%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldNyxoah does not currently pay a dividend.Dividend GrowthNyxoah does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NYXH. Previous Next 2.5 News and Social Media Coverage News SentimentNyxoah has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Nyxoah this week, compared to 1 article on an average week.Search InterestOnly 3 people have searched for NYXH on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.MarketBeat Follows2 people have added Nyxoah to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Nyxoah insiders have not sold or bought any company stock.Percentage Held by Insiders17.11% of the stock of Nyxoah is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Nyxoah are expected to remain at ($1.78) per share in the coming year.Price to Earnings Ratio vs. the MarketThe P/E ratio of Nyxoah is -8.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nyxoah is -8.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNyxoah has a P/B Ratio of 2.66. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Gold Safe ExchangeTrump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… About Nyxoah Stock (NASDAQ:NYXH)Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.Read More NYXH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NYXH Stock News HeadlinesMarch 26, 2024 | markets.businessinsider.comBuy Rating Affirmed for Nyxoah’s Genio System Amid Strategic Partnerships and Market Capture PotentialMarch 25, 2024 | americanbankingnews.comHC Wainwright Analysts Increase Earnings Estimates for Nyxoah S.A. (NASDAQ:NYXH)March 29, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.March 25, 2024 | globenewswire.comNyxoah Advances Patient Access Strategy through Partnership with the American Association of Otolaryngology – Head & Neck Surgery FoundationMarch 21, 2024 | americanbankingnews.comNyxoah (NASDAQ:NYXH) Price Target Raised to $27.00 at Stifel NicolausMarch 21, 2024 | americanbankingnews.comNyxoah (NASDAQ:NYXH) Given Buy Rating at HC WainwrightMarch 21, 2024 | americanbankingnews.comNyxoah S.A. (NASDAQ:NYXH) Receives $18.40 Consensus PT from BrokeragesMarch 20, 2024 | markets.businessinsider.comBuy Rating Affirmed for Nyxoah Amid Promising DREAM Study Results and Market Growth ProjectionsMarch 29, 2024 | Crypto 101 Media (Ad)SHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. March 20, 2024 | americanbankingnews.comHead to Head Review: Nyxoah (NASDAQ:NYXH) & Accuray (NASDAQ:ARAY)March 19, 2024 | msn.comNyxoah says Genio pivotal study meets primary endpointsMarch 19, 2024 | globenewswire.comNyxoah Announces DREAM U.S. Pivotal Study Meets Primary EndpointsMarch 7, 2024 | seekingalpha.comNyxoah S.A. (NYXH) Q4 2023 Earnings Call TranscriptMarch 7, 2024 | finance.yahoo.comNyxoah S.A. (NASDAQ:NYXH) Q4 2023 Earnings Call TranscriptMarch 6, 2024 | markets.businessinsider.comBuy Rating Affirmed for Nyxoah Amid Record Genio Sales and Strong Growth ProspectsMarch 5, 2024 | investorplace.comNYXH Stock Earnings: Nyxoah Misses EPS, Beats Revenue for Q4 2023March 5, 2024 | globenewswire.comNyxoah Reports Fourth Quarter and Financial Year 2023 Financial and Operating ResultsMarch 4, 2024 | benzinga.comPreview: Nyxoah's EarningsFebruary 29, 2024 | globenewswire.comNyxoah to Participate in the Oppenheimer 34th Annual Healthcare MedTech & Services ConferenceFebruary 26, 2024 | msn.comButterfly Network, ThermoGenesis among healthcare moversFebruary 15, 2024 | finance.yahoo.comNyxoah to Release Fourth Quarter and Financial Year 2023 Financial Results on March 5, 2024February 15, 2024 | globenewswire.comNyxoah to Release Fourth Quarter and Financial Year 2023 Financial Results on March 5, 2024February 9, 2024 | morningstar.comNyxoah SA Ordinary Shares NYXHJanuary 17, 2024 | finance.yahoo.comNyxoah Announces 2024 Strategic PrioritiesJanuary 10, 2024 | msn.comNyxoah expects to almost double revenue in 4Q23January 9, 2024 | finance.yahoo.comNyxoah Announces Preliminary Results for the Fourth Quarter and Full Year 2023December 12, 2023 | markets.businessinsider.comBuy Rating on Nyxoah’s Genio System Amid Strong Market Potential and Positive Clinical DataSee More Headlines Receive NYXH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nyxoah and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/05/2024Today3/29/2024Next Earnings (Estimated)5/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:NYXH CUSIPN/A CIK1857190 Webwww.nyxoah.com Phone321-022-2355Fax321-045-9075Employees137Year FoundedN/APrice Target and Rating Average Stock Price Target$20.60 High Stock Price Target$27.00 Low Stock Price Target$14.00 Potential Upside/Downside+52.7%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.68) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-46,770,000.00 Net Margins-993.28% Pretax Margin-1,027.03% Return on Equity-38.58% Return on Assets-31.24% Debt Debt-to-Equity Ratio0.12 Current Ratio4.73 Quick Ratio4.50 Sales & Book Value Annual Sales$4.70 million Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.08 per share Price / Book2.66Miscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable Beta1.51 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Robert Taub MBA (Age 77)Co-Founder & Chairman Comp: $84.24kMr. Olivier Taelman (Age 52)CEO & Executive Director Comp: $689.68kMr. Loic Moreau (Age 44)Chief Financial Officer Comp: $346.42kMr. Bruno OnkelinxChief Technology OfficerMikaela KirkwoodCorporate Communication & Investor Relations ManagerMs. An MoonenGeneral CounselMr. Remi RenardVice President of Market & Market AccessMs. Inge VanwittenberghGlobal Human Resource DirectorMr. David M. DeMartinoChief Strategy OfficerMr. Jeyakumar SubbaroyanChief Clinical OfficerMore ExecutivesKey Competitors180 Life SciencesNASDAQ:ATNFW60 Degrees PharmaceuticalsNASDAQ:SXTPWAclarionNASDAQ:ACONWAinosNASDAQ:AIMDWAlpha Tau MedicalNASDAQ:DRTSWView All CompetitorsInstitutional OwnershipGoldman Sachs Group Inc.Sold 39,559 shares on 3/1/2024Ownership: 0.000%Opaleye Management Inc.Sold 97,096 shares on 2/15/2024Ownership: 1.383%Goldman Sachs Group Inc.Sold 39,559 shares on 2/13/2024Ownership: 0.000%View All Institutional Transactions NYXH Stock Analysis - Frequently Asked Questions Should I buy or sell Nyxoah stock right now? 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Nyxoah in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" NYXH shares. View NYXH analyst ratings or view top-rated stocks. What is Nyxoah's stock price target for 2024? 6 brokerages have issued 12 month target prices for Nyxoah's stock. Their NYXH share price targets range from $14.00 to $27.00. On average, they expect the company's stock price to reach $20.60 in the next year. This suggests a possible upside of 52.7% from the stock's current price. View analysts price targets for NYXH or view top-rated stocks among Wall Street analysts. How have NYXH shares performed in 2024? Nyxoah's stock was trading at $4.64 on January 1st, 2024. Since then, NYXH shares have increased by 190.7% and is now trading at $13.49. View the best growth stocks for 2024 here. Are investors shorting Nyxoah? Nyxoah saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 290,900 shares, an increase of 65.6% from the February 29th total of 175,700 shares. Based on an average trading volume of 59,200 shares, the short-interest ratio is currently 4.9 days. Currently, 3.1% of the shares of the company are short sold. View Nyxoah's Short Interest. When is Nyxoah's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 21st 2024. View our NYXH earnings forecast. How were Nyxoah's earnings last quarter? Nyxoah S.A. (NASDAQ:NYXH) announced its quarterly earnings data on Tuesday, March, 5th. The company reported ($0.41) EPS for the quarter, hitting analysts' consensus estimates of ($0.41). The business earned $1.96 million during the quarter, compared to the consensus estimate of $2.01 million. Nyxoah had a negative net margin of 993.28% and a negative trailing twelve-month return on equity of 38.58%. What guidance has Nyxoah issued on next quarter's earnings? Nyxoah issued an update on its fourth quarter 2023 earnings guidance on Tuesday, January, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $2.0 million-$2.0 million, compared to the consensus revenue estimate of $1.5 million. When did Nyxoah IPO? Nyxoah (NYXH) raised $83 million in an IPO on Friday, July 2nd 2021. The company issued 2,760,000 shares at a price of $30.00 per share. Who are Nyxoah's major shareholders? Nyxoah's stock is owned by many different institutional and retail investors. Top institutional shareholders include Opaleye Management Inc. (1.38%), Goldman Sachs Group Inc. (0.00%) and Goldman Sachs Group Inc. (0.00%). How do I buy shares of Nyxoah? Shares of NYXH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NYXH) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 Media“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyOnly a fool would buy Nvidia today… Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nyxoah S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.